In recent years, the serum PON1 activity has been reported to be reduced in several types of malignancies, such as lung cancer, gastrointestinal cancer, breast and prostate cancer, bladder cancer, central nervous system tumors, non-Hodgkin’s lymphoma, and acute lymphoblastic lymphoma [23,24]. Here, PON1 is linked to prostate cancer.